News

  • 9 December 2021

    Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended September 30, 2021.

  • 7 December 2021

    Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or Sequana Medical), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from six patients in SAHARA DESERT, the safety and feasibility study of alfapump DSR (Direct Sodium Removal) in heart failure patients with persistent congestion.

  • 6 December 2021

    Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the completion of patient enrolment in POSEIDON, the North American pivotal study to support regulatory approval of the alfapump system in the U.S. and Canada, for the treatment of recurrent or refractory ascites due to liver cirrhosis.

  • 10 November 2021

    Sonendo, Inc., (NYSE: SONX) a leading dental technology company and developer of the GentleWave® System, today announced it has treated over 700,000 patients with its GentleWave® System, an alternative to traditional root canal therapy (RCT) backed by years of research and peer-reviewed clinical outcomes. This milestone comes after the company's recent IPO on October 29, 2021.

  • 28 October 2021

    Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced the pricing of its initial public offering of 7,800,000 shares of its common stock at a public offering price of $12.00 per share, for total gross proceeds of $93.6 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by Sonendo. Sonendo’s common stock is expected to begin trading on the New York Stock Exchange on October 29, 2021, under the ticker symbol "SONX." The offering is expected to close on November 2, 2021, subject to the satisfaction of customary closing conditions. In addition, Sonendo has granted the underwriters a 30-day option to purchase up to an additional 1,170,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.